Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Factors to consider before choosing EV labeling method for fluorescence-based techniques

doi: 10.3389/fbioe.2024.1479516

Figure Lengend Snippet: Common label types.

Article Snippet: Ptx-OG (paclitaxel Oregon Green) , Creative Bioarray , fluorescent dye conjugate of the chemotherapy drug paclitaxel , selective labeling, minimal interference, high fluorescence quantum yield, photostability , potential for nonspecific binding, paclitaxel cytotoxicity , may impact EV protein function and sorting , EV uptake and intracellular trafficking , .

Techniques: Staining, Membrane, Labeling, Live Cell Imaging, Binding Assay, Functional Assay, In Vitro, Fluorescence, Imaging, In Vivo, In Vivo Imaging, Solubility, Concentration Assay, Liposomes, Microscopy, Flow Cytometry, Permeability, Modification, Disruption, Avidin-Biotin Assay, Isolation, Expressing

Journal: Molecular pharmaceutics

Article Title: Backbone Degradable N -(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts

doi: 10.1021/acs.molpharmaceut.6b01005

Figure Lengend Snippet: In vivo efficacy of HPMA copolymer–drug conjugates against A2780 human ovarian tumor xenografts. Tumor cells (5 × 106/mouse) were inoculated subcutaneously on the back, and administration started when the tumor size reached ~100–200 mm3 (n = 5). As a comparison, sequential combination therapy of 2P–PTX followed by 2P–GEM was also plotted in both cases. (A) Tumor growth was inhibited by gemcitabine monotherapy. Intravenous injection three times with a 7-day interval. (B) Tumor growth was inhibited by paclitaxel monotherapy with a single intravenous administration on day. The dose of conjugate for each injection is expressed as a dose equivalent to free drug gemcitabine (5 mg/kg) or paclitaxel (20 mg/kg).

Article Snippet: Paclitaxel (PTX, > 99.5%) was purchased from LC Laboratories (Woburn, MA).

Techniques: In Vivo, Injection

Journal: Molecular pharmaceutics

Article Title: Backbone Degradable N -(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts

doi: 10.1021/acs.molpharmaceut.6b01005

Figure Lengend Snippet: (A) In vivo efficacy of degradable diblock copolymer–GEM conjugates and PTX conjugates against A2780 human ovarian tumor xenografts. Tumor cells (5 × 106/mouse) were inoculated subcutaneously on the back of nude mice, and administration started when the tumor size reached ~100–200 mm3 (n = 5). Tumor growth was inhibited by either monotherapy or combination therapy. Intravenous and intraperitoneal injections were conducted, respectively. The doses of conjugates (gemcitabine 5 mg/kg × 3 on days 0, 7, 14 and paclitaxel 20 mg/kg on day 0) are in drug equivalent. (B) Body-weight change.

Article Snippet: Paclitaxel (PTX, > 99.5%) was purchased from LC Laboratories (Woburn, MA).

Techniques: In Vivo

Journal: Bioactive Materials

Article Title: Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine

doi: 10.1016/j.bioactmat.2020.11.016

Figure Lengend Snippet: Schematic illustration of the targeted and intelligent nano-platform with controllable UCST for co-delivery of paclitaxel and curcumin, and the mechanistic action of achieving immunogenic cell death and reversing immunosuppression.

Article Snippet: Paclitaxel (PTX) was purchased from Shanghai Knowshine Pharmachemicals Inc. (China).

Techniques:

Journal: Cancer Science

Article Title: Apoptosis signal‐regulating kinase‐1 inhibitor as a potent therapeutic drug for the treatment of gastric cancer

doi: 10.1111/cas.12024

Figure Lengend Snippet: K811 prevents gastric cancer cell proliferation in vitro. (a) Numbers of MKN45 cells at 24, 48 and 72 h after treatment with K811 or vehicle (Cont.). K811 (0.5–1 μM) was administered every 24 h. (b) Relative numbers of the indicated cells 72 h after treatment with K811 (0.5–3 μM). Data show the mean ± SD. *P < 0.05 versus vehicle. (c) AGS, Hela and 293T cells were transfected with control, ASK1‐HA or mutant HER2‐expressing vectors and cultured with or without K811 (1 μM) for 4 h. (d) Relative numbers of MKN45 cells 48 h after treatment with K811 (2 μM), 5‐FU (10 μM), paclitaxel (PTX) (0.4 μM), vehicle or a combination of these drugs. The mean cell number for control cells was set to 1.0. Data show the mean ± SD. *P < 0.05.

Article Snippet: 5‐FU and paclitaxel (PTX) were purchased from Wako Chemical Industries (Osaka, Japan).

Techniques: In Vitro, Transfection, Mutagenesis, Expressing, Cell Culture